达格列净、依普利酮及其联合治疗对慢性肾脏病患者白蛋白尿的降低作用:一项随机交叉临床试验
该随机开放标签交叉试验纳入46例已接受最大耐受剂量ACEI或ARB且尿白蛋白排泄≥100 mg/24h、eGFR 30-90 ml/min/1.73m²的CKD患者,比较达格列净10 mg/日、依普利酮50 mg/日及其联合治疗4周对24小时UACR的影响。结果显示联合治疗降低UACR达53%,优于单药,且达格列净与依普利酮的UACR变化不相关。
要点
- 达格列净与依普利酮降低UACR的作用不相关,支持系统性地轮换这两种疗法以优化治疗。
- 达格列净联合依普利酮产生稳健的附加降UACR效应,联合治疗UACR降幅达53%。
- 依普利酮组高钾血症发生率高于达格列净组和联合治疗组(17.4% vs 0% vs 4.3%,组间P=0.003)。
核心结论
- 达格列净与依普利酮引起的白蛋白尿变化不相关,支持系统性地轮换这些疗法以优化治疗。
- 达格列净联合依普利酮产生稳健的附加降UACR效应。
- 需要在该人群中开展更大规模的试验以确认SGLT2抑制剂联合MRA治疗的长期疗效和安全性。
研究设计与样本
- 随机开放标签交叉试验,筛选57例,随机分配46例,平均eGFR 58.1 ml/min/1.73m²,中位UACR 401 mg/g。
- 患者被随机分配至达格列净10 mg/日、依普利酮50 mg/日或二者联合治疗4周,治疗期间以4周洗脱期分隔。
- 纳入标准为尿白蛋白排泄≥100 mg/24h、eGFR 30-90 ml/min/1.73m²,且已接受最大耐受稳定剂量ACEI或ARB治疗。
主要发现
- 治疗4周后,达格列净组UACR较基线平均百分比变化为-19.6%(95%CI -34.3至-1.5)。
- 依普利酮组UACR较基线平均百分比变化为-33.7%(95%CI -46.1至-18.5)。
- 达格列净-依普利酮联合组UACR较基线平均百分比变化为-53%(95%CI -61.7至-42.4;与达格列净组比较P<0.001;与依普利酮组比较P=0.01)。
- 达格列净治疗期间UACR变化与联合治疗期间UACR变化不相关(r=-0.13;P=0.47),依普利酮治疗期间UACR变化与联合治疗期间UACR变化不相关(r=-0.08;P=0.66)。
- 高钾血症在依普利酮组报告更频繁(n=8;17.4%),达格列净组为n=0;0%,联合组为n=2;4.3%(组间P=0.003)。
关键数值与推荐
- 主要结局为不同治疗间UACR变化的相关性。
- 次要结局为24小时UACR较基线的百分比变化。
临床怎么用
- 作者认为,达格列净与依普利酮降低白蛋白尿的作用不相关,支持系统性地轮换这些疗法以优化治疗。
- 作者指出,达格列净联合依普利酮产生稳健的附加降UACR效应。
- 作者提出,需要在该人群中开展更大规模的试验以确认SGLT2抑制剂联合MRA治疗的长期疗效和安全性。
局限性
- 需要在该人群中开展更大规模的试验以确认SGLT2抑制剂联合MRA治疗的长期疗效和安全性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Sodium glucose cotransporter 2 (SGLT2) inhibitors and mineralocorticoid receptor antagonists (MRAs) reduce the urinary albumin-to-creatinine ratio (UACR) and confer kidney and cardiovascular protection in patients with CKD. We assessed efficacy and safety of the SGLT2 inhibitor dapagliflozin and MRA eplerenone alone and in combination in patients with CKD. METHODS: We conducted a randomized open-label crossover trial in patients with urinary albumin excretion ≥100 mg/24 hr, eGFR 30-90 ml/min per 1.73 m2, who had been receiving maximum tolerated stable doses of an ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB). Patients were assigned to 4-week treatment periods with dapagliflozin 10 mg/day, eplerenone 50 mg/day, or their combination in random order, separated by 4-week washout periods. Primary outcome was the correlation in UACR changes between treatments. Secondary outcome was the percent change in 24-hour UACR from baseline. RESULTS: Of 57 patients screened, 46 were randomly assigned (mean eGFR, 58.1 ml/min per 1.73 m2; median UACR, 401 mg/g) to the three groups. Mean percentage change from baseline in UACR after 4 weeks of treatment with dapagliflozin, eplerenone, and dapagliflozin-eplerenone was -19.6% (95% confidence interval [CI], -34.3 to -1.5), -33.7% (95% CI, -46.1 to -18.5), and -53% (95% CI, -61.7 to -42.4; P<0.001 versus dapagliflozin; P=0.01 versus eplerenone). UACR change during dapagliflozin or eplerenone treatment did not correlate with UACR change during dapagliflozin-eplerenone (r=-0.13; P=0.47; r=-0.08; P=0.66, respectively). Hyperkalemia was more frequently reported with eplerenone (n=8; 17.4%) compared with dapagliflozin (n=0; 0%) or dapagliflozin-eplerenone (n=2; 4.3%; P between-groups=0.003). CONCLUSIONS: Albuminuria changes in response to dapagliflozin and eplerenone did not correlate, supporting systematic rotation of these therapies to optimize treatment. Combining dapagliflozin with eplerenone resulted in a robust additive UACR-lowering effect. A larger trial in this population is required to confirm long-term efficacy and safety of combined SGLT2 inhibitor and MRA treatment. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: European Union Clinical Trials Register, EU 2017-004641-25.
引用
- Provenzano M, Puchades MJ, Garofalo C, et al. Albuminuria-Lowering Effect of Dapagliflozin, Eplerenone, and Their Combination in Patients with Chronic Kidney Disease: A Randomized Crossover Clinical Trial. J Am Soc Nephrol. 2022. PMID: 35440501. doi:10.1681/ASN.2022020207
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。